The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review)

Shigetomi,Hiroshi; Oonogi,Akira; Tsunemi,Taihei; Tanase,Yasuhito; Yamada,Yoshihiko; Kajihara,Hirotaka; Yoshizawa,Yoriko; Furukawa,Naoto; Haruta,Shoji; Yoshida,Shozo; Sado,Toshiyuki; Oi,Hidekazu; Kobayashi,Hiroshi

doi:10.3892/ol.2011.316

The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review)

Authors:
- Hiroshi Shigetomi
- Akira Oonogi
- Taihei Tsunemi
- Yasuhito Tanase
- Yoshihiko Yamada
- Hirotaka Kajihara
- Yoriko Yoshizawa
- Naoto Furukawa
- Shoji Haruta
- Shozo Yoshida
- Toshiyuki Sado
- Hidekazu Oi
- Hiroshi Kobayashi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan
Published online on: May 16, 2011 https://doi.org/10.3892/ol.2011.316
Pages: 591-597

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent data have provided information regarding the profiles of clear cell carcinoma of the ovary (CCC) with adenine-thymine rich interactive domain 1A (ARID1A) mutations. The purpose of this review was to summarize current knowledge regarding the molecular mechanisms involved in CCC tumorigenesis and to describe the central role played by the aberrant chromatin remodeling. The present article reviews the English-language literature for biochemical studies on the ARID1A mutation and chromatin remodeling in CCC. ARID1A is responsible for directing the SWI/SNF complex to target promoters and regulates the transcription of certain genes by altering the chromatin structure around those genes. The mutation spectrum of ARID1A was enriched for C to T transitions. CCC and clear cell renal cell carcinoma (ccRCC) resemble each other pathogenetically. Dysfunction of the ARID1A protein, which occurs with VHL mutations in ccRCC, is responsible for loss of the assembly of the ARID1A-mediated histone H2B complex. Therefore, ARID1A acts as a chromatin remodeling modifier, which stimulates cell signaling that can lead to cell cycle arrest and cell death in the event of DNA damage. The dysfunction of ARID1A may result in susceptibility to CCC carcinogenesis through a defect in the repair or replication of damaged DNA.

View Figures

View References

1	Piver MS: Prophylactic oophorectomy: reducing the U.S. death rate from epithelial ovarian cancer. A continuing debate. Oncologist. 1:326–330. 1996.PubMed/NCBI
2	Kennedy AW, Biscotti CV, Hart WR and Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol. 32:342–349. 1998. View Article : Google Scholar
3	Ryu SY, Park SI, Nam BH, et al: Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol. 20:1032–1036. 2009. View Article : Google Scholar : PubMed/NCBI
4	Viganó P, Somigliana E, Chiodo I, Abbiati A and Vercellini P: Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Reprod Update. 12:77–89. 2006.PubMed/NCBI
5	Kobayashi H, Sumimoto K, Moniwa N, et al: Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 17:37–43. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol. 18(Suppl 2): S19–S32. 2005. View Article : Google Scholar : PubMed/NCBI
7	Jiang X, Hitchcock A, Bryan EJ, et al: Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res. 56:3534–3539. 1996.PubMed/NCBI
8	Kobayashi H, Kajiwara H, Kanayama S, et al: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review). Oncol Rep. 22:233–240. 2009.PubMed/NCBI
9	Yoo AS and Crabtree GR: ATP-dependent chromatin remodeling in neural development. Curr Opin Neurobiol. 19:120–126. 2009. View Article : Google Scholar : PubMed/NCBI
10	Weissman B and Knudsen KE: Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res. 69:8223–8230. 2009. View Article : Google Scholar : PubMed/NCBI
11	Osipovich OA, Subrahmanyam R, Pierce S, Sen R and Oltz EM: Cutting edge: SWI/SNF mediates antisense Igh transcription and locus-wide accessibility in B cell precursors. J Immunol. 183:1509–1513. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kundu S and Peterson CL: Role of chromatin states in transcriptional memory. Biochim Biophys Acta. 1790:445–455. 2009. View Article : Google Scholar : PubMed/NCBI
13	Rodriguez-Nieto S and Sanchez-Cespedes M: BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis. 30:547–554. 2009. View Article : Google Scholar : PubMed/NCBI
14	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
15	Toyota M and Suzuki H: Epigenetic drivers of genetic alterations. Adv Genet. 70:309–323. 2010. View Article : Google Scholar : PubMed/NCBI
16	Fan D, Ma C and Zhang H: The molecular mechanisms that underlie the tumor suppressor function of LKB1. Acta Biochim Biophys Sin (Shanghai). 41:97–107. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hess J, Angel P and Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hydbring P and Larsson LG: Cdk2: a key regulator of the senescence control function of Myc. Aging. 2:244–250. 2010.PubMed/NCBI
19	Bogliolo M, Cabré O, Callén E, et al: The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis. 17:529–538. 2002. View Article : Google Scholar : PubMed/NCBI
20	Sansam CG and Roberts CW: Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle. 5:621–624. 2006. View Article : Google Scholar : PubMed/NCBI
21	Watanabe H, Mizutani T, Haraguchi T, et al: SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene. 25:470–479. 2006.PubMed/NCBI
22	Luo B, Cheung HW, Subramanian A, et al: Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA. 105:20380–20385. 2008. View Article : Google Scholar : PubMed/NCBI
23	Crow E, Du Z and Li L: New insights into prion biology from the novel [SWI⁺] system. Prion. 2:141–144. 2008.
24	Mertens F, Johansson B, Höglund M and Mitelman F: Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 57:2765–2780. 1997.PubMed/NCBI
25	Nagl NG Jr, Patsialou A, Haines DS, et al: The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 65:9236–9244. 2005. View Article : Google Scholar : PubMed/NCBI
26	Wang X, Nagl NG Jr, Flowers S, et al: Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 112:6362004. View Article : Google Scholar : PubMed/NCBI
27	Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
28	Jones S, Wang TL, Shih IeM, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wilsker D, Patsialou A, Dallas PB and Moran E: ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 13:95–106. 2002.PubMed/NCBI
30	Li XS, Trojer P, Matsumura T, Treisman JE and Tanese N: Mammalian SWI/SNF – a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. Mol Cell Biol. 30:1673–1688. 2010.
31	Gilbert PM, Mouw JK, Unger MA, et al: HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest. 120:1535–1550. 2010. View Article : Google Scholar : PubMed/NCBI
32	Dehennaut V and Leprince D: Implication of HIC1 (hypermethylated in cancer 1) in the DNA damage response. Bull Cancer. 96:E66–E72. 2009.PubMed/NCBI
33	Van Rechem C, Boulay G and Leprince D: HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun. 385:586–590. 2009.PubMed/NCBI
34	Iaquinta PJ and Lees JA: Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol. 19:649–657. 2007. View Article : Google Scholar : PubMed/NCBI
35	Ma K, Araki K, Ichwan SJ, et al: E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. Mol Cancer Res. 1:438–444. 2003.PubMed/NCBI
36	Kim YT and Zhao M: Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J. 46:597–613. 2005. View Article : Google Scholar : PubMed/NCBI
37	Bourdon JC: p53 and its isoforms in cancer. Br J Cancer. 97:277–282. 2007. View Article : Google Scholar : PubMed/NCBI
38	Staehling-Hampton K, Ciampa PJ, Brook A and Dyson N: A genetic screen for modifiers of E2F in Drosophila melanogaster. Genetics. 153:275–287. 1999.PubMed/NCBI
39	Roesch A, Mueller AM, Stempfl T, et al: RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer. 122:1047–1057. 2008. View Article : Google Scholar : PubMed/NCBI
40	Zorn KK, Bonome T, Gangi L, et al: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 11:6422–6430. 2005. View Article : Google Scholar : PubMed/NCBI
41	Gnarra JR, Tory K, Weng Y, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:85–90. 1994. View Article : Google Scholar : PubMed/NCBI
42	Hacker KE, Lee CM and Rathmell WK: VHL type 2B mutations retain VBC complex form and function. PLoS One. 3:E38012008. View Article : Google Scholar : PubMed/NCBI
43	Vodermaier HC: APC/C and SCF: controlling each other and the cell cycle. Curr Biol. 14:R787–R796. 2004. View Article : Google Scholar : PubMed/NCBI
44	Clark PE: The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 76:939–945. 2009. View Article : Google Scholar : PubMed/NCBI
45	Beisel C, Imhof A, Greene J, Kremmer E and Sauer F: Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature. 419:857–862. 2002.PubMed/NCBI
46	Ezhkova E and Tansey WP: Proteasomal ATPases link ubiquitylation of histone H2B to methylation of histone H3. Mol Cell. 13:435–442. 2004. View Article : Google Scholar : PubMed/NCBI
47	Atanassov BS, Koutelou E and Dent SY: The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett. Oct 26–2010.(Epub ahead of print).
48	Dalgliesh GL, Furge K, Greenman C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 463:360–363. 2010. View Article : Google Scholar
49	Wang JK, Tsai MC, Poulin G, et al: The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev. 24:327–332. 2010. View Article : Google Scholar : PubMed/NCBI
50	Newbold RF and Mokbel K: Evidence for a tumour suppressor function of SETD2 in human breast cancer: a new hypothesis. Anticancer Res. 30:3309–3311. 2010.PubMed/NCBI
51	Duns G, van den Berg E, van Duivenbode I, et al: Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70:4287–4291. 2010. View Article : Google Scholar : PubMed/NCBI
52	Kurman RJ and Shih IeM: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 27:151–160. 2008.PubMed/NCBI
53	Kajihara H, Yamada Y, Kanayama S, et al: Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
54	Sufan RI, Jewett MA and Ohh M: The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 287:F1–F6. 2004. View Article : Google Scholar : PubMed/NCBI